L-theanine attenuates LPS-induced motor deficit in experimental rat model of Parkinson’s disease: emphasis on mitochondrial activity, neuroinflammation, and neurotransmitters
Rationale Parkinson’s disease (PD) is a neurodegenerative disorder characterized by loss of dopaminergic neurons. The pathogenesis of PD includes oxidative stress, mitochondrial dysfunction, neuroinflammation, and neurotransmitter dysregulation. L-theanine is found in green tea and has antioxidant, anti-inflammatory, and neuroprotective effects with a high blood brain barrier permeability. Objective The objective of this study was to investigate the possible neuroprotective effect of L-theanine in lipopolysaccharide (LPS) induced motor deficits and striatal neurotoxicity in a rat model of PD. Methods LPS was infused at a dose of 5 μg/5 μl PBS stereotaxically into SNpc of rats. Treatment with L-theanine (50 and 100 mg/kg; po) and Sinemet (36 mg/kg; po) was given from day 7 to 21 in of LPS injected rat. On a weekly basis all behavioral parameters were assessed, and animals were sacrificed on day 22. The striatum tissue of brain was isolated for biochemicals (Nitrite, GSH, catalase, SOD, mitochondrial complexes I and IV), neuroinflammatory markers, and neurotransmitters (serotonin, dopamine, norepinephrine, GABA, and glutamate) estimations. Results Results revealed that L-theanine dose-dependently and significantly reversed motor deficits, assessed through locomotor and rotarod activity. Moreover, L-theanine attenuated biochemical markers, reduced oxidative stress, and neurotransmitters dysbalance in the brain. L-theanine treatment at 100 mg/kg; po substantially reduced these pathogenic events by increasing mitochondrial activity, restoring neurotransmitter levels, and inhibiting neuroinflammation. Conclusions These data suggest that the positive effects of L-theanine on motor coordination may be mediated by the suppression of NF-κB induced by LPS. Therefore, L-theanine would have a new therapeutic potential for PD..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:240 |
|---|---|
| Enthalten in: |
Psychopharmacology - 240(2023), 7 vom: 16. Mai, Seite 1493-1508 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kumar, Shivam [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
L-theanine |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s00213-023-06382-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR051904942 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR051904942 | ||
| 003 | DE-627 | ||
| 005 | 20230616064659.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230616s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00213-023-06382-y |2 doi | |
| 035 | |a (DE-627)SPR051904942 | ||
| 035 | |a (SPR)s00213-023-06382-y-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kumar, Shivam |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a L-theanine attenuates LPS-induced motor deficit in experimental rat model of Parkinson’s disease: emphasis on mitochondrial activity, neuroinflammation, and neurotransmitters |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Rationale Parkinson’s disease (PD) is a neurodegenerative disorder characterized by loss of dopaminergic neurons. The pathogenesis of PD includes oxidative stress, mitochondrial dysfunction, neuroinflammation, and neurotransmitter dysregulation. L-theanine is found in green tea and has antioxidant, anti-inflammatory, and neuroprotective effects with a high blood brain barrier permeability. Objective The objective of this study was to investigate the possible neuroprotective effect of L-theanine in lipopolysaccharide (LPS) induced motor deficits and striatal neurotoxicity in a rat model of PD. Methods LPS was infused at a dose of 5 μg/5 μl PBS stereotaxically into SNpc of rats. Treatment with L-theanine (50 and 100 mg/kg; po) and Sinemet (36 mg/kg; po) was given from day 7 to 21 in of LPS injected rat. On a weekly basis all behavioral parameters were assessed, and animals were sacrificed on day 22. The striatum tissue of brain was isolated for biochemicals (Nitrite, GSH, catalase, SOD, mitochondrial complexes I and IV), neuroinflammatory markers, and neurotransmitters (serotonin, dopamine, norepinephrine, GABA, and glutamate) estimations. Results Results revealed that L-theanine dose-dependently and significantly reversed motor deficits, assessed through locomotor and rotarod activity. Moreover, L-theanine attenuated biochemical markers, reduced oxidative stress, and neurotransmitters dysbalance in the brain. L-theanine treatment at 100 mg/kg; po substantially reduced these pathogenic events by increasing mitochondrial activity, restoring neurotransmitter levels, and inhibiting neuroinflammation. Conclusions These data suggest that the positive effects of L-theanine on motor coordination may be mediated by the suppression of NF-κB induced by LPS. Therefore, L-theanine would have a new therapeutic potential for PD. | ||
| 650 | 4 | |a Parkinson’s disease |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Lipopolysaccharide |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a L-theanine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Neurotransmitters |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a NF-κB |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Awasthi, Anupam |4 aut | |
| 700 | 1 | |a Raj, Khadga |4 aut | |
| 700 | 1 | |a Singh, Shamsher |0 (orcid)0000-0002-2780-6632 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Psychopharmacology |d Berlin : Springer, 1959 |g 240(2023), 7 vom: 16. Mai, Seite 1493-1508 |w (DE-627)SPR001983342 |w (DE-600)2066933-1 |x 1432-2072 |7 nnns |
| 773 | 1 | 8 | |g volume:240 |g year:2023 |g number:7 |g day:16 |g month:05 |g pages:1493-1508 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00213-023-06382-y |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 240 |j 2023 |e 7 |b 16 |c 05 |h 1493-1508 | ||